US EditionCurevac Filed a Patent Dispute over Covid-19 Vaccines with Biontech/pfizer
Summary by Der Standard DE
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.3 Articles
3 Articles
Curevac receives a total of 740 million dollars. This was announced by the company based in Tübingen
CureVacReposted by 
bionity.com
bionity.comTÜBINGEN, Germany/BOSTON, USA – August 7-8, 2025CureVac N.V. (Nasdaq: CVAC), a global biopharmaceutical company that is developing a new drug class based on messenger ribonucleic acid (mRNA), today announced that CureVac N.V. and a related company (together, CureVac) as well as a related company of GSK plc (LSE/NYSE: GSK, GSK) have entered into agreements with BioNTech SE (Nasdaq: BNTX) and a related company (together, BioNTech), as well as Pfiz…
Coverage Details
Total News Sources3
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
